



I hereby certify that this correspondence is being deposited with the United States Patent and as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on May 16, 2001.

Glenn P. Ladwig  
Glenn P. Ladwig, Patent Attorney

67-1645  
PRELIMINARY AMENDMENT 5-2501  
Examining Group 1645  
Patent Application  
Docket No. UF-221C1XC1  
Serial No. 09/662,254  
RZ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit : 1645  
Applicant(s) : Richard W. Moyer, Yi Li, Allison L. Bawden  
Serial No. : 09/662,254  
Filed : September 14, 2000  
For : Materials and Methods for Delivery and Expression of Heterologous DNA in Vertebrate Cells

Assistant Commissioner for Patents  
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Please amend the following application to read as follows:

In the Specification:

Please substitute the first paragraph of the Brief Summary of the Invention found at page 5, line 23 through Page 6, line 3, with the following paragraph:

21  
The subject invention concerns a novel viral vector system for gene therapy based on an insect poxvirus designed to deliver genes for integration and stable, permanent expression in vertebrate cells. In an exemplified embodiment, a recombinant AmEPV vector was constructed that contains heterologous genes under the control of promoters that drive the expression of the heterologous genes in vertebrate cells. The *gfp* gene and the gene encoding G418 resistance were used in an exemplified construct. The recombinant AmEPV was used to infect vertebrate cells and following infection the cells were transferred to media containing G418. Cells expressing both GFP